P-340. Adaptation of a Pharmacist-Led Long-Acting Injectable (LAI) Antiretroviral Therapy (ART) Program to Increase Use of LAI ART in Arkansas, an Ending the HIV Epidemic (EHE) Jurisdiction

P-340. 调整药剂师主导的长效注射抗逆转录病毒疗法 (LAI) 项目,以提高阿肯色州(终结艾滋病流行 (EHE) 管辖区)LAI ART 的使用率

阅读:1

Abstract

BACKGROUND: Barriers to adherence to daily oral ART can lead to poor clinical outcomes and propagation of HIV transmission. LAI ART is a promising alternative for persons with HIV (PWH) who struggle with adherence or prefer a non-oral option. Access to LAI ART for PWH has been complicated by administrative, clinical, and logistical barriers. The Miriam Hospital Infectious Diseases & Immunology Center (TMH ID Center) in Providence, Rhode Island established a successful pharmacist-led LAI ART program overcoming implementation barriers. This study sought to adapt and pilot a similar program at ARcare, a Ryan White-funded Federally Qualified Health Center (FQHC) with multiple HIV clinics in Arkansas, an EHE-designated jurisdiction. [Figure: see text] [Figure: see text] METHODS: This was a two-year study supported by the Providence/Boston Center for AIDS Research (P30AI042853). Leveraging the procedures and insights from the TMH ID Center LAI ART Program, we adapted a pharmacy-led LAI ART program (Figure 1) through the development of a Collaborative Practice Agreement (CPA) between pharmacists and providers across ARcare clinics. Implementation was supported by weekly meetings between ARcare and TMH to discuss clinical and logistical challenges. Guided by the Exploration, Preparation, Implementation, Sustainment (EPIS) and Reach, Effectiveness, Adoption, Implementation, Maintenance (RE-AIM) frameworks, we used quantitative and qualitative data to assess program reach, adherence, effectiveness, maintenance, and implementation barriers/facilitators. RESULTS: Since CPA approval in January 2024, 65 patients were referred. Figure 2 describes quantitative results. Key differences between programs included health system structure, staffing, and LAI ART eligibility criteria. Qualitative interviews with leadership and staff found the program acceptable and feasible, with improvements in overall care coordination, verification of clinical eligibility, and benefits investigation. Persistent barriers included limited clinic capacity and insurance approval. CONCLUSION: A pharmacist-led LAI ART model is feasible and sustainable in FQHCs and adaptable to diverse health system and staffing structures. Broader replication, implementation, and evaluation across a larger sample of clinics are warranted. DISCLOSURES: Jure Baloh, PhD, ViiV Healthcare: Grant/Research Support Gabriella A. Douglass, PharmD, AAHIVP, BCACP, Gilead - FOCUS Partnership: Grant/Research Support Ashlyn Curry, PharmD, AAHIVP, Focus Program - Gilead Sciences: Grant/Research Support Elma Abdullah, PharmD, Gilead/FOCUS: Grant/Research Support

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。